Shandong Sipond Pharmaceutical

Shandong Sipond Pharmaceutical is a clinical-stage biopharmaceutical company headquartered in Jinan, China, focused on the discovery and development of innovative small molecule drugs. The company primarily targets autoimmune diseases and oncology, leveraging its internal research and development platform to create highly selective therapeutic agents. Its lead program, SP-002, is a selective Janus kinase 1 (JAK1) inhibitor currently in Phase 2 clinical trials for indications including rheumatoid arthritis and atopic dermatitis. Sipond aims to address significant unmet medical needs by providing high-quality, innovative treatments for patients in China and international markets. The company has established a comprehensive infrastructure that spans from early-stage drug discovery to clinical development and manufacturing.